# Lavine Hemlani

Lavine Hemlani is a founder and business operator who writes about building companies, financial operations for founders, biotech partnerships, and investment opportunities in the Gulf. Their posts draw on examples from customer onboarding, fundraising, and business development to explain practical decisions founders face.

- Profile: https://b2binfluencer.marketing/creators/lavine-hemlani/
- LinkedIn: https://www.linkedin.com/in/lavine-hemlani
- LinkedIn followers: 17,309
- Topics: startup
- Based on 23 dated posts, latest 2026-09-30

## Summary

They are useful for providing grounded perspectives on company building, financial operations, and investment in the Gulf.

- Best for: Expert-led briefings or co-hosted sessions for biotech venture funds or life sciences teams.
- Not for: They are not suitable for direct-to-consumer wellness campaigns or supplement promotions.
- Check first: Confirm paid terms, deliverables, and whether a sponsorship offer exists before proceeding.

### Takeaways

- Watching customers handle their work can reveal product problems a demo misses.
- Gulf capital sits with families and sovereign funds, not venture funds.
- Biotech business development is described as orchestration, not just pitching.

## Main ideas

- **Founders should keep judgment and outsource everything with a deadline and a template**: The argument is that a founder's only real asset is the work nobody else can do, and that time spent on bookkeeping, payroll, tax credits or filing mechanics takes away from it. Lavine Hemlani recommends keeping capital allocation, the story and decisions about key people, and outsourcing the rest. The same test applies to finance hires: a bookkeeper records what happened; a strategic CFO builds the milestone model and investor-ready data room that close a round. The suggested interview question: would this person build a burn-to-milestone model or just pull last month's actuals? They go further, arguing that the right engagement is not a fraction of a person but an operator embedded inside the company—a phrase borrowed from Palantir and heard from a founder who took a biotech public at a billion-dollar valuation. Hemlani's firm, Zenith, sells fractional CFO work to companies doing $1M to $50M+ in revenue; that is the service being described.
- **Gulf capital sits with families and sovereign funds, not venture funds. The pitch has to match where the wealth was made**: The starting point is scale: all the venture capital raised in the UAE in one year was $2 billion, compared with $2.5 trillion held by seven institutions; fintech took about a quarter of the venture total. The advice: story is not leverage, traction is, because terms improve month by month. A second rule is to match the story to the source of the investor's wealth. Families that built fortunes in regional real estate, trade or manufacturing respond to a domestic-capability pitch; a foreign family office that merely keeps an office in Dubai needs a different one. The third rule reframes the competition: it is not other startups but local real estate and monopoly stocks such as the water company or the parking authority. If a deal cannot beat the water company, they say, do not take the meeting. Dubai and Abu Dhabi are treated as two different wallets: Dubai took almost all UAE tech funding in a quarter, while Abu Dhabi holds sovereign and industrial money.
- **The UAE is trying to own the whole biotech stack under one decision-maker**: The argument is that biotech's bottleneck was never the science but everything around it: capital in one country, regulators in another, manufacturing offshore, genomic data locked in separate hospitals, patients somewhere else. The UAE, they write, can put every piece under one roof and move quickly, through Mubadala's holdings, with drug discovery now its largest investment sector; a Longevity Authority chaired at crown-prince level; new biopharma manufacturing campuses; and a national genomics program feeding drug development. They note that the West keeps the best scientists and that the UAE makes under 5% of the medicine it uses. The execution challenge is finding people who can turn a sovereign mandate into a company. A companion post contrasts the US, where venture dollars into biotech stayed near a record while biotech's share of US venture funding fell to just above 8% as AI absorbed more than half of it, with Gulf funds that have ring-fenced multi-billion-dollar life-science portfolios.
- **Biotech business development is orchestration, not pitching**: Lavine Hemlani argues that because most newly approved drugs come from biotech companies rather than large pharma, deal-making is the machine that produces the industry's output—and the people who run it need more than charm. They list the requirements: defending the science through months of diligence; understanding the full chain, from regulatory and clinical work to manufacturing and market access; access to the specific person inside a large pharma who needs the asset; structuring milestone-based deals rather than naming a price; and having personally closed deals. The structuring point carries the most weight: upfront cash is only about 7% of total deal value, with the rest paid over years and contingent on the science working. Their practical test for anyone offering to do business development: have you closed one of these, start to finish?
- **A profitable services business is not a failed software company**: Lavine Hemlani calls this the most expensive lesson they have learned: they tried the conversion themself and watched others pour a profitable consulting business into a cash-hungry product bet. Their counterargument is arithmetic: a tech-enabled service already trades at 13 to 18 times earnings, capturing most of the software upside without becoming a different kind of business. A companion argument, drawn from onboarding multi-entity supply chain customers, is that services are the source of the product, not its enemy. The messy manual work done for customer three becomes the playbook productized for customer thirty; the founder should onboard the first ten customers personally.
- **Accumulated judgment is the real asset, and most of it is inaccessible**: The claim is that a person's most valuable asset is not their network or capital but years of pattern recognition built from deals, mistakes and conversations—and that it sits unused in notes nobody reopens and emails nobody can find. Their answer is a system they call the 2nd Brain, built on a concept they credit to AI researcher Andrej Karpathy, in which the AI maintains the knowledge base. Add a meeting note, article or voice memo, and it writes a structured page and links it to what is already stored, so a conversation about a client's financial structure from months ago surfaces alongside a framework saved last week.
- **The most valuable businesses sit where several domains meet**: After a day in Shenzhen, the observation that stayed with Lavine Hemlani was not the robots or the scale of the electronics market but the people who run it. They describe them as translators who speak hardware, software, logistics and market trends at once: they can take a sketch from a European designer, know what a factory needs to produce it, identify which component supplier can deliver same-day, and judge whether a market in Dubai will pay for it. Their conclusion: high-value businesses are built at the intersection of several fields, not at the centre of one.

## Work to read

- [2.5 trillion sits in seven institutions in the UAE](https://www.linkedin.com/posts/lavine-hemlani_25-trillion-sits-in-seven-institutions-activity-7479836522255388673-4Dxm)
- [The UAE makes less than 5 of its own medicine today](https://www.linkedin.com/posts/lavine-hemlani_the-uae-makes-less-than-5-of-its-own-medicine-activity-7483436832953790465-pkAL)
- [Biopharma partnerships: The most active year in the industry's history](https://www.linkedin.com/posts/lavine-hemlani_270-billion-flowed-through-biopharma-partnerships-activity-7488819560201187328-IAec)
- [US venture capital just poured a near-record amount into biotech](https://www.linkedin.com/posts/lavine-hemlani_us-venture-capital-just-poured-a-near-record-activity-7478108057827291137-Kdvi)
- [A founder I know watched a sovereign investor go from "you're too early" to wanting 30% of his company](https://www.linkedin.com/posts/lavine-hemlani_a-founder-i-know-watched-a-sovereign-investor-activity-7477636401115631617-eLnK)
- [Last night i spoke with a founder who took a biotech public at a billion-dollar valuation](https://www.linkedin.com/posts/lavine-hemlani_last-night-i-spoke-with-a-founder-who-took-activity-7477636401115631617-eLnK)
- [Founders tell me: "We tried a fractional CFO. It didn't really work."](https://www.linkedin.com/posts/lavine-hemlani_founders-telling-me-we-tried-a-fractional-activity-7474784487386611712-3kdh)
- [Most founders want to automate everything from Day 1](https://www.linkedin.com/posts/lavine-hemlani_most-founders-want-to-automate-everything-activity-7444199942266667008-5GFY)
- [Hiring: Appointment Setter (USA/Canada based)](https://www.linkedin.com/posts/lavine-hemlani_zenith-financial-infrastructure-that-scales-activity-7437816138304192512--eZE)
- [The most expensive lesson I've learned: don't turn a services business into software](https://www.linkedin.com/posts/lavine-hemlani_the-most-expensive-lesson-ive-learned-dont-activity-7490778667330228224-tLjs)
- [Your most valuable asset isn't your network or your capital](https://www.linkedin.com/posts/lavine-hemlani_your-most-valuable-asset-isnt-your-network-activity-7465358191929966592-y3Rz)
- [The thing that struck me wasn't the robots or the scale of Huaqiangbei](https://www.linkedin.com/posts/lavine-hemlani_i-spent-a-day-in-shenzhen-the-thing-that-activity-7465636412206297088-NeLy)

## Brand relationships

- **Zenith** (disclosed_partnership)
- **Midas** (mention)

## Partnerships

Lavine Hemlani's posts document a small number of commercial formats rather than a media kit: paid fractional CFO and embedded finance engagements, co-hosted live educational sessions, and outsourced finance, grant, and regulatory execution for life-science founders. The services sit around Zenith, described in the posts as a fractional CFO practice for companies doing roughly $1M–$50M+ in revenue, and finance and business-development support for biotech founders. Before pursuing a sponsorship, ask for pricing, deliverables, and the right contact route.

## Alternatives

- Dan Lewis: Choose Dan Lewis when the briefing needs current pharma deal flow and regulatory movement, or when a portfolio company needs to build and qualify a manufacturing site. One post is a dated roundup of industry events: a $15.2B Bristol Myers Squibb licensing deal with Jiangsu Hengrui across 13 early-stage programs, FDA leadership departures, Takeda's plan to cut 4,500 jobs by March 2027, Eli Lilly's Mounjaro becoming the top-selling drug in Q1 2026 at $8.7B, Daiichi Sankyo's oncology targets, the EU's provisional Critical Medicines Act covering about 270 drugs, and Isomorphic Labs raising $2.1B for AI drug design. The other explains the completed acquisition of SimoTech by Project Farma and PerkinElmer, arguing that digital manufacturing, automation, CQV and operational readiness should be aligned across the facility lifecycle rather than fixed one discipline at a time. For a fund tracking licensing activity or backing a company building a biotech facility, that material is closer to day-to-day decisions than a Gulf capital briefing.
- Ghazi Benothman: Choose Ghazi Benothman when the fund's priority is early-stage deep-tech sourcing rather than Gulf capital strategy. In one post, they describe a small-ticket programme writing €50,000 SAFE notes to first-time founders from Tunisia and the diaspora. It is limited to deep tech—life sciences, cybersecurity, B2B AI, semiconductors, quantum, drones and robotics—with fintech, mobility and local hobby projects explicitly excluded; pitches are reviewed with a named partner at MEDIN. The other post interprets the Anthropic Economic Index for Tunisia, arguing that the country uses AI as a production tool rather than a consumption one, and points to software development, math and computer-science theory, and devops work as distinctive categories. For a fund seeking North African or diaspora deep-tech founders at demo stage and beyond, that is the lane they describe.
- Matthew Holt: Choose Matthew Holt when a portfolio company's blocker is procurement and supplier negotiation in life sciences, or when the BD team needs sharper meeting habits before a partnering conference. As co-founder of Collaborative Sourcing, a procurement consultancy for life-science industries, they argue that procurement is usually brought in late because organisations have already decided its role is to get a better price on a chosen supplier. By then, most available value is fixed, and procurement is judged on savings against a baseline it did not set. Their CPHI advice is specific and portable: arrive with two or three questions you genuinely need answered, ask how the other side actually chooses between suppliers rather than what they need, follow up within 48 hours referencing something exact they said, and resist overselling in the room.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/